Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.65 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.65 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409666 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL409667 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL6540887 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL13303640 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL410119 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL13303673 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL13303643 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL13303629 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL13303641 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| SCHEMBL12052455 | 1.00 | SLC6A4 (0.67) | SLC6A4KCNA5SCN5AKCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207219-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2012-06-26 | — | — | US | disclosed |
| US-8163938-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2011-01-06 | — | — | US | disclosed |
| US-7820712-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-20100120890-A1 | ION CHANNEL MODULATING ACTIVITY I | CARDIOME PHARMA CORP. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-7674820-B2 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2010-03-09 | — | — | US | disclosed |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | CARDIOME PHARMA CORP. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-7507545-B2 | Ion channel modulating activity method | CARDIOME PHARMA CORP. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | CARDIOME PHARMA CORP. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2008-08-07 | — | — | US | disclosed |
| US-7345086-B2 | Uses of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-7345087-B2 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2008-03-18 | — | — | US | disclosed |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041841-A1 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS | KCNN3, KCNN2, KCNN1 | SLC6A4 173/4885KCNA5 78/4885SCN5A 59/4885 |
| US-20110004006-A1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | KCNH2, KCNC1, KCNH3 | SLC6A4 1837/4885KCNA5 16/4885SCN5A 24/4885 |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | SLC6A4 1837/4885KCNA5 16/4885SCN5A 24/4885 |
| US-20100120890-A1 | ION CHANNEL MODULATING ACTIVITY I | KCNN1, KCNN3, KCNH1 | SLC6A4 439/4885KCNA5 45/4885SCN5A 71/4885 |
| US-20090270478-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNN2 | SLC6A4 511/4885KCNA5 31/4885SCN5A 59/4885 |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | SLC6A4 1837/4885KCNA5 16/4885SCN5A 24/4885 |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | SLC6A4 296/4885KCNA5 48/4885SCN5A 49/4885 |
| US-20120095073-A1 | ION CHANNEL MODULATING ACTIVITY II | KCNH1, KCNN3, KCNJ2 | SLC6A4 493/4885KCNA5 34/4885SCN5A 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.